Sulzer (SUN) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
28 Jul, 2026Executive summary
Flow and Services divisions demonstrated growth and improved profitability despite a challenging environment, while Chemtech stabilized its core business but faced headwinds from delayed large projects and is undergoing accelerated restructuring.
Profitability improved with EBITDA margin rising to 15.5% in H1 2026 from 12.9% in H1 2023, marking the fourth consecutive year of margin growth.
Commercial and operational excellence initiatives contributed to margin improvements and resilience across divisions.
Order pipeline for the second half of the year remains strong, supporting a positive outlook.
Delivered solid financial results in H1 2026 despite geopolitical and macroeconomic headwinds, with resilience in core and aftermarket business lines.
Financial highlights
Sales increased by 1.0% year-over-year to CHF 1,673 million, with growth in Flow and Services offsetting Chemtech declines.
Order intake decreased by 3.9% year-over-year to CHF 1,787 million, impacted by fewer large orders and currency effects.
EBITDA margin rose by 110 basis points to 15.5%, with EBITDA at CHF 258.7 million (up 3.1%).
Free cash flow dropped to CHF 12.8 million due to increased net working capital from delayed and paused projects.
Gross profit margin improved by 130 bps to 34.9%.
Outlook and guidance
Full-year 2026 guidance confirmed: order intake growth of 1–5%, sales growth of 2–5%, and EBITDA margin around 16.5%.
Larger project orders expected to be back-end loaded in Q4, with increasing customer planning activity observed.
Continued focus on cost reduction, operational excellence, and strategic growth areas.
Latest events from Sulzer
- Q1 2026 order intake fell 8.6% year-over-year, but guidance and outlook for 2026 remain positive.SUN
Q1 2026 TU - Record sales, profit, and margins support a higher dividend and positive 2026 outlook.SUN
H2 2025 - Order intake recovers, Services grow double digits, Chemtech hit by delays; guidance reaffirmed.SUN
Q3 2025 TU - Sales, EBITDA, and net income up; Chemtech lagged, outlook and dividend increased.SUN
H1 2025 - Stable Q1 order intake and confirmed guidance, with strong Flow and Services growth.SUN
Q1 2025 TU - Order intake up 9.2% year-over-year; full-year guidance and profitability targets reaffirmed.SUN
Q3 2024 TU - Order and sales growth drove higher profitability and upgraded 2024 guidance.SUN
H1 2024 - Targets above-market growth, >17% EBITDA margin, >22% ROCE, driven by innovation and efficiency.SUN
CMD 2024 - Double-digit sales and order growth, higher margins, and strong 2025 outlook driven by backlog.SUN
H2 2024